Acrux Limited (ACR.AX)
- Previous Close
0.0580 - Open
0.0590 - Bid 0.0630 x 25336600
- Ask 0.0640 x 1874200
- Day's Range
0.0590 - 0.0640 - 52 Week Range
0.0350 - 0.0990 - Volume
165,762 - Avg. Volume
841,560 - Market Cap (intraday)
17.443M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 18, 2015
- 1y Target Est
--
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.
www.acrux.com.auRelated News
Performance Overview: ACR.AX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACR.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACR.AX
Valuation Measures
Market Cap
17.44M
Enterprise Value
15.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.51
Price/Book (mrq)
3.09
Enterprise Value/Revenue
1.33
Enterprise Value/EBITDA
-7.02
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.21%
Return on Assets (ttm)
-15.12%
Return on Equity (ttm)
-12.21%
Revenue (ttm)
11.42M
Net Income Avi to Common (ttm)
-709k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
4.57M
Total Debt/Equity (mrq)
40.07%
Levered Free Cash Flow (ttm)
-1.36M